New Guidelines Provide Evidence-Based Recommendations for Treating Eosinophilic Esophagitis

May 2, 2020

A new guideline from the American Gastroenterological Association (AGA) and the Joint Task Force for Allergy-Immunology Practice Parameters provides recommendations for the management of eosinophilic esophagitis (EoE) in paediatric and adult patients.

The guideline, published in Annals of Allergy, Asthma & Immunology and Gastroenterology, recommends topical steroids as first-line treatment for EoE; and proton pump inhibition (PPI) therapy, diet therapy, and esophageal dilation as treatment options.

The use of novel, targeted biologic therapies for EoE are being actively evaluated but more research is needed before these can be recommended.

“Over the past two decades, EoE has emerged as a dominant cause of swallowing difficulties worldwide,” said Ikuo Hirano, MD, Northwestern University Feinberg School of Medicine, Chicago, Illinois. “The recommendations we’ve outlined will guide allergists and gastroenterologists in effectively managing their patients’ EoE and improving their quality of life.”

“As the field moves forward, a deeper understanding of the natural history of EoE in both children and adults is needed to inform clinical decisions regarding the optimal use of disease monitoring and long-term, maintenance therapy,” he added.

This guideline was developed through a collaboration between AGA and the Joint Task Force for Allergy-Immunology Practice Parameters, which comprises the American College of Allergy, Asthma & Immunology and the American Academy of Allergy, Asthma & Immunology.

An accompanying clinical decision support tool can be found here:

Reference: and

SOURCE: American College of Allergy, Asthma and Immunology